SeaSun Biomaterials (CEO Hee-kyung Park) was selected as the lead organization for the project of'Big Data-based ADHD and Intellectual Disability Diagnosis-Development of Next-Generation Platform for Treatment' of the'Bio Industry Core Technology Development Project' supported by the Ministry of Trade, Industry and Energy. Sun said.

Seoul National University Hospital (Professor Kim Bung-nyeon's team) and AI (artificial intelligence) specialized company Acryl Co., Ltd. will participate in this project with government support of 3 billion won over the next three years and nine months.

The next generation platform for diagnosis and treatment is an objective and quantitative early diagnosis of attention deficit hyperactivity disorder (ADHD) and intellectual disability, which has an incidence rate of about 15% in children and school-age children, through the discovery of genome-based biomarkers and the development of analysis algorithms. And to present treatment guidelines.

ADHD and intellectual disability are caused by congenital genetic causes and environmental epigenetic causes. By developing an artificial intelligence learning algorithm using genome and epigenome information and various medical data for patients, we will revalidate the existing diagnosis method and discover new biomarkers to develop artificial intelligence diagnosis technology based on big data. Is expected.

Park Hee-kyung, the head of the subjective research, said, "At present, most of the diagnosis of ADHD and intellectual disability is based on questionnaire responses or behavioral symptoms. This time, the convergence of genomic big data and artificial intelligence technology will greatly contribute to the diagnosis and treatment of mental disorders. I look forward to it.”